Rating Change
Cantor Fitzgerald reiterated its Overweight rating on Vaxcyte, Inc. Common Stock (NASDAQ:PCVX) on October 12, 2026.
reiterateNASDAQ:PCVX
Cantor Fitzgerald Reiterates Overweight Rating on Vaxcyte, Inc. Common Stock (PCVX)
Cantor Fitzgerald reiterated its Overweight rating on Vaxcyte, Inc. Common Stock (NASDAQ:PCVX) on October 12, 2026.
At publication ·
What changed
Vaxcyte, Inc. Common Stock (NASDAQ:PCVX) · reiterate
- Firm
- Cantor Fitzgerald
- Rating
- Overweight to Overweight
- Price at event
- $70.65
- Market capitalization
- $5.8B
At a glance
Key takeaways
- Cantor Fitzgerald reiterated an Overweight rating on Vaxcyte (PCVX) on October 12, 2026, with the stock trading at $70.65.
Market Context
Vaxcyte, Inc. Common Stock operates in the Healthcare sector. The stock currently trades at $70.65 with a market capitalization of $5.8B. The stock has gained 62.1% over the past 52 weeks.
Analyst coverage from Cantor Fitzgerald provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Vaxcyte, Inc. Common Stock.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Vaxcyte, Inc. Common Stock
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 12, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Oct 05, 2026 | Needham | Buy | N/A |
| Oct 05, 2026 | BTIG | Buy | N/A |
| Oct 05, 2026 | Guggenheim | Buy | N/A |
| Sep 28, 2026 | B of A Securities | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View PCVX Stock Page
Frequently Asked Questions
What does the Overweight rating mean for PCVX?
A rating of Overweight from Cantor Fitzgerald reflects the analyst's outlook on Vaxcyte, Inc. Common Stock (NASDAQ:PCVX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the PCVX forecast page.